Skip to main content
Top
Published in: Rheumatology International 6/2012

01-06-2012 | Original Article

Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis

Authors: Eiman Soliman, W. Labib, G. El-tantawi, A. Hamimy, A. Alhadidy, A. Aldawoudy

Published in: Rheumatology International | Issue 6/2012

Login to get access

Abstract

The objective of this study is to evaluate the role of MMP-3 and MRI in assessing disease activity in sacroiliac joints of AS patients in comparison to the conventional measures Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Serum MMP-3 was measured in 30 patients who fulfilled the modified New York criteria for AS and in ten healthy volunteers. AS patients were categorized into those having high or low MMP-3 according to a cut-off value = 7.1 ng/ml. MRI of the sacroiliac joints (SIJs) was performed on all patients. SIJs were evaluated for enhancement and subchondral bone marrow edema. Results of MMP-3 and findings on MRI were correlated with multiple clinical parameters including BASDAI, ESR and CRP. Serum MMP-3 was significantly elevated in AS patients with active disease. Elevated MMP-3 levels were significantly associated with high BASDAI (P = 0.046), but not with ESR or CRP. MRI showed bone marrow edema and enhancement of SIJs in 19/30 patients with one patient showing enhancement only. These MRI findings were not correlated with MMP-3, BASDAI, CRP or ESR. In conclusion, serum MMP-3 is an objective measure reflecting clinical disease activity in AS. Bone marrow edema and enhancement detected by MRI of SIJs is another objective measure of disease activity, but are not correlated with MMP-3 or the conventional parameters as BASDAI, ESR, or CRP. Although both MMP-3 and MRI can reflect disease activity in AS they seem to be unrelated, perhaps each is reflecting a different aspect of disease activity. MMP-3 and MRI should be considered together with BASDAI in assessing disease activity and in guiding the available recommendations for initiation of biologics in AS.
Literature
1.
go back to reference Sengupta R, Stone MA (2007) The assessment of ankylosing spondylitis in clinical practice. Nat Clin Pract Rheumatol 3(9):496–503PubMedCrossRef Sengupta R, Stone MA (2007) The assessment of ankylosing spondylitis in clinical practice. Nat Clin Pract Rheumatol 3(9):496–503PubMedCrossRef
2.
go back to reference Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–452. doi:10.1136/ard.2005.041137 Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65:442–452. doi:10.​1136/​ard.​2005.​041137
3.
go back to reference Garrett S, Jenkinson T, Kennedy G, BASDAI et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–91 Garrett S, Jenkinson T, Kennedy G, BASDAI et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–91
4.
go back to reference Yildirim K, Erdal A, Karatay S et al (2004) Relationship between some acute phase reactants and the Bath ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J 97:350–353PubMedCrossRef Yildirim K, Erdal A, Karatay S et al (2004) Relationship between some acute phase reactants and the Bath ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J 97:350–353PubMedCrossRef
5.
go back to reference Hembry RM, Bagga MR, Reynolds JJ et al (1995) Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 54:25–32PubMedCrossRef Hembry RM, Bagga MR, Reynolds JJ et al (1995) Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 54:25–32PubMedCrossRef
7.
go back to reference Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839PubMedCrossRef Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839PubMedCrossRef
8.
go back to reference MacNaul KL, Chartrain N, Lark M, Tocci MJ et al (1990) Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 265:17238–17245PubMed MacNaul KL, Chartrain N, Lark M, Tocci MJ et al (1990) Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 265:17238–17245PubMed
9.
go back to reference Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMed Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMed
10.
go back to reference Ribbens C, Martin y Porras M, Franchimont N et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRef Ribbens C, Martin y Porras M, Franchimont N et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166PubMedCrossRef
11.
go back to reference Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942–2953PubMedCrossRef Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942–2953PubMedCrossRef
12.
go back to reference Chen C, Lin K, Yu D et al (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 45:414–420PubMedCrossRef Chen C, Lin K, Yu D et al (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology 45:414–420PubMedCrossRef
13.
go back to reference Lukas C, Braun J, van der Heijde D et al (2007) Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 34:862–70 Lukas C, Braun J, van der Heijde D et al (2007) Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 34:862–70
14.
go back to reference Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J (1994) Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 37:1039–1045PubMedCrossRef Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J (1994) Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 37:1039–1045PubMedCrossRef
15.
go back to reference Bennett AN, Marzo-Ortega H, Emery P et al (2009) Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis International Society criteria: MRI entering centre stage. Ann Rheum Dis 68:765–767PubMedCrossRef Bennett AN, Marzo-Ortega H, Emery P et al (2009) Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis International Society criteria: MRI entering centre stage. Ann Rheum Dis 68:765–767PubMedCrossRef
16.
go back to reference Weber U, Maksymowych WP (2008) How does imaging help the clinician in the evaluation and management of spondyloarthritis? Skeletal Radiol 37:487–490PubMedCrossRef Weber U, Maksymowych WP (2008) How does imaging help the clinician in the evaluation and management of spondyloarthritis? Skeletal Radiol 37:487–490PubMedCrossRef
17.
go back to reference Braun J, Landewe R, Hermann KG, Han J et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652PubMedCrossRef Braun J, Landewe R, Hermann KG, Han J et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652PubMedCrossRef
18.
go back to reference van der Linden S, Valkenberg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef van der Linden S, Valkenberg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMedCrossRef
19.
go back to reference van Tubergan A, Debates I, Ryser L et al (2002) Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum 47:242–248CrossRef van Tubergan A, Debates I, Ryser L et al (2002) Use of a numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. Arthritis Rheum 47:242–248CrossRef
20.
go back to reference Jones SD, Steiner A, Calin A et al (1996) The Bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 35:66–71PubMedCrossRef Jones SD, Steiner A, Calin A et al (1996) The Bath ankylosing spondylitis patient global score (BAS-G). Br J Rheumatol 35:66–71PubMedCrossRef
21.
go back to reference Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
22.
go back to reference Jenkinson T, Mallorie P, Whitelock H et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed Jenkinson T, Mallorie P, Whitelock H et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed
23.
go back to reference Dougados M, Hermann K-G, Landewé R et al (2009) The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68:ii1–ii44 Dougados M, Hermann K-G, Landewé R et al (2009) The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68:ii1–ii44
24.
go back to reference Docherty P, Mitchell MJ, MacMillan L et al (1992) Magnetic resonance imaging in the detection of sacroiliitis. J Rheumatol 19:393–401PubMed Docherty P, Mitchell MJ, MacMillan L et al (1992) Magnetic resonance imaging in the detection of sacroiliitis. J Rheumatol 19:393–401PubMed
25.
go back to reference Lewis SM (2001) Miscellaneous tests. In: Lewis SM, Bum BJ, Bates I (eds) Dacie and Lewis practical haematology, 9th edn. Churchill Livingstone, London, pp 527–531 Lewis SM (2001) Miscellaneous tests. In: Lewis SM, Bum BJ, Bates I (eds) Dacie and Lewis practical haematology, 9th edn. Churchill Livingstone, London, pp 527–531
26.
go back to reference Taylor DJ, Cheung NT, Dawes PT (1994) Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 53:768–772PubMedCrossRef Taylor DJ, Cheung NT, Dawes PT (1994) Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 53:768–772PubMedCrossRef
27.
go back to reference Zochling J, Braun J (2005) Assessment of ankylosing spondylitis. Clin Exp Rheumatol 23:S133–S141PubMed Zochling J, Braun J (2005) Assessment of ankylosing spondylitis. Clin Exp Rheumatol 23:S133–S141PubMed
28.
go back to reference Calin A, Nakache JP, Geuguen A et al (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 38:878–882PubMedCrossRef Calin A, Nakache JP, Geuguen A et al (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology 38:878–882PubMedCrossRef
29.
go back to reference Spoorenberg A, van Tubergen A, Landewe R et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology 44:789–795PubMedCrossRef Spoorenberg A, van Tubergen A, Landewe R et al (2005) Measuring disease activity in ankylosing spondylitis: patient and physician have different perspectives. Rheumatology 44:789–795PubMedCrossRef
30.
go back to reference Spoorenberg A, van der Heijde D, de Klerk E, Dougados M et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26:980–984PubMed Spoorenberg A, van der Heijde D, de Klerk E, Dougados M et al (1999) Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 26:980–984PubMed
31.
go back to reference Sheehan NJ, Slavin BM, Donovan MP et al (1986) Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute-phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 25:171–174PubMedCrossRef Sheehan NJ, Slavin BM, Donovan MP et al (1986) Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute-phase proteins or protease inhibitors in ankylosing spondylitis. Br J Rheumatol 25:171–174PubMedCrossRef
32.
go back to reference Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F (2007) Acute-phase response clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 74:249–253PubMedCrossRef Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F (2007) Acute-phase response clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 74:249–253PubMedCrossRef
33.
go back to reference Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966e70 Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966e70
34.
go back to reference Chunhua Y, Gu J, Rihl M et al (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691–699CrossRef Chunhua Y, Gu J, Rihl M et al (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691–699CrossRef
35.
go back to reference Wendling D, Cedoz J, Racadot E (2008) Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFa antagonist therapy. Joint Bone Spine 75(5):559–562PubMedCrossRef Wendling D, Cedoz J, Racadot E (2008) Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFa antagonist therapy. Joint Bone Spine 75(5):559–562PubMedCrossRef
36.
go back to reference Puhakka K, Jurik A, Schiottz-Christensenl B et al (2004) Magnetic resonance imaging of sacroiliitis in early seronegative spondylarthropathy. Abnormalities correlated to clinical and laboratory findings. Rheumatology 43:234–237PubMedCrossRef Puhakka K, Jurik A, Schiottz-Christensenl B et al (2004) Magnetic resonance imaging of sacroiliitis in early seronegative spondylarthropathy. Abnormalities correlated to clinical and laboratory findings. Rheumatology 43:234–237PubMedCrossRef
37.
go back to reference Woo J, Lee H, Sung I et al (2007) Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. Rheumatology 34:1753–1759 Woo J, Lee H, Sung I et al (2007) Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. Rheumatology 34:1753–1759
38.
go back to reference Goh L, Suresh P, Gafoor A, Hughes P, Hickling P (2008) Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol 27(4):449–455PubMedCrossRef Goh L, Suresh P, Gafoor A, Hughes P, Hickling P (2008) Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol 27(4):449–455PubMedCrossRef
39.
go back to reference Visvanathan S, Wagner C, Marini JC et al (2007) Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 67:511–517. doi:10.1136/ard.2007.071605 Visvanathan S, Wagner C, Marini JC et al (2007) Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 67:511–517. doi:10.​1136/​ard.​2007.​071605
40.
go back to reference Jee W, McCauley T, Lee S et al (2004) Sacroiliitis in patients with ankylosing spondylitis: association of MR findings with disease activity. Magn Reson Imaging 22:245–250PubMedCrossRef Jee W, McCauley T, Lee S et al (2004) Sacroiliitis in patients with ankylosing spondylitis: association of MR findings with disease activity. Magn Reson Imaging 22:245–250PubMedCrossRef
41.
go back to reference Jarrett SJ, Sivera F, Cawkwell LS, Marzo-Ortega H, McGonagle D, Hensor E, Coates L, O’Connor PJ, Fraser A, Conaghan PG, Emery P (2009) MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 68:1466–1469. doi:10.1136/ard.2008.092213 Jarrett SJ, Sivera F, Cawkwell LS, Marzo-Ortega H, McGonagle D, Hensor E, Coates L, O’Connor PJ, Fraser A, Conaghan PG, Emery P (2009) MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 68:1466–1469. doi:10.​1136/​ard.​2008.​092213
42.
go back to reference Bredella MA, Steinbach LS, Morgan S, Ward M, Davis JC (2006) MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis. AJR 187:1420–1426PubMedCrossRef Bredella MA, Steinbach LS, Morgan S, Ward M, Davis JC (2006) MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis. AJR 187:1420–1426PubMedCrossRef
43.
go back to reference Song H, Rudwaleit M, Listing J et al (2009) Comparison of the BASDAI and the modified BASDAI (mini-BASDAI) in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis. 68(11):1701–1707. doi:10.1136/ard.2008.099226 Song H, Rudwaleit M, Listing J et al (2009) Comparison of the BASDAI and the modified BASDAI (mini-BASDAI) in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. Ann Rheum Dis. 68(11):1701–1707. doi:10.​1136/​ard.​2008.​099226
44.
go back to reference Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24. doi:10.1136/ard.2008.094870 Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24. doi:10.​1136/​ard.​2008.​094870
45.
go back to reference van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R, for the Assessment of SpondyloArthritis international Society (ASAS) (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818. doi:10.1136/ard.2008.100826 van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R, for the Assessment of SpondyloArthritis international Society (ASAS) (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818. doi:10.​1136/​ard.​2008.​100826
46.
go back to reference Rudwaleit M, Schwarzlose S, Hilgert ES et al (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67:1276–1281PubMedCrossRef Rudwaleit M, Schwarzlose S, Hilgert ES et al (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67:1276–1281PubMedCrossRef
47.
go back to reference Lord P, Farragher T, Lunt M et al (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology. Biol Register Rheumatol 49(3):563–570 Lord P, Farragher T, Lunt M et al (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology. Biol Register Rheumatol 49(3):563–570
48.
go back to reference Maksymowych W, Rahman P, Shojania K et al (2008) Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. Rheumatology 35:2030–2037 Maksymowych W, Rahman P, Shojania K et al (2008) Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. Rheumatology 35:2030–2037
49.
go back to reference Maksymowych W, Poole A, Hiebert L et al (2005) Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32:1911–1917PubMed Maksymowych W, Poole A, Hiebert L et al (2005) Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 32:1911–1917PubMed
50.
go back to reference Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853PubMedCrossRef Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853PubMedCrossRef
Metadata
Title
Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis
Authors
Eiman Soliman
W. Labib
G. El-tantawi
A. Hamimy
A. Alhadidy
A. Aldawoudy
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-1852-8

Other articles of this Issue 6/2012

Rheumatology International 6/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.